Diagnostic tests are expensive and time-consuming to develop. Early economic evaluation using decision modeling can reduce commercial risk by providing early evidence on cost-effectiveness. The National Institute for Health Research Diagnostic Evidence Co-operatives (DECs) was established to catalyze evidence generation for diagnostic tests by collaborating with commercial developers; DEC researchers have consequently made extensive use of early modeling. The aim of this article is to summarize the experiences of the DECs using early modeling for diagnostics. We draw on 8 case studies to illustrate the methods, highlight methodological strengths and weaknesses particular to diagnostics, and provide advice. The case studies covered diagnosis, screening, and treatment stratification. Treatment effectiveness was a crucial determinant of cost-effectiveness in all cases, but robust evidence to inform this parameter was sparse. This risked limiting the usability of the results, although characterization of this uncertainty in turn highlighted the value of further evidence generation. Researchers evaluating early models must be aware of the importance of treatment effect evidence when reviewing the cost-effectiveness of diagnostics. Researchers planning to develop an early model of a test should also 1) consult widely with clinicians to ensure the model reflects real-world patient care; 2) develop comprehensive models that can be updated as the technology develops, rather than taking a ''quick and dirty'' approach that may risk producing misleading results; and 3) use flexible methods of reviewing evidence and evaluating model results, to fit the needs of multiple decision makers. Decision models can provide vital information for developers at an early stage, although limited evidence mean researchers should proceed with caution.
Medical tests are ubiquitous in modern medicine. They can be used not only to diagnose disease but also to monitor patients and provide a prognosis. With the rise of screening programs, decision tools, and guidelines, medicine is coming to rely more greatly on accurate medical tests. 1 New tests require evaluation to assess cost-effectiveness, but this is a more complex proposition than for new treatments, which have a direct effect on patient outcomes. Medical tests instead tend to affect patient health only indirectly, by guiding the choice of treatment used. 1 The cost-effectiveness of a test therefore depends not only on diagnostic accuracy but also the downstream impact of a given diagnosis on patient management and in turn the cost-effectiveness of interventions used. At *These authors contributed equally. the same time, many tests are developed by small biotechnology companies who lack the resources to conduct trials with a relevant primary health outcome. 2 In this high-risk commercial landscape, test developers may benefit from using decision modeling methods to assess the potential for cost-effectiveness earlier in the research and development (R&D) pipeline.
Early economic evaluation provides an initial assessment of whether a technology has the potential to be cost-effective and under which conditions, before significant resources have been invested in its development. An early economic model typically relies on the literature, expert opinion, and early-phase test-specific clinical evidence to build a decision model that represents the intended clinical pathway for the technology under evaluation. Many of the model parameters are likely to be subject to great uncertainty, but scrutiny of the model can identify which model parameters are important determinants of final cost-effectiveness. 3 Early modeling is not intended to guide the adoption decisions made by organizations such as the National Institute for Health and Care Excellence (NICE) but instead to inform those engaged in the research and development process, such as manufacturers, investors, and public funding bodies. On the basis of early costeffectiveness evidence, a developer has the opportunity to refine their technology to better meet clinical need, reposition their technology within the same or an alternate care pathway, or abandon a diagnostic technology that is highly unlikely to be cost-effective. 4 It is thought that early modeling has been used extensively in pharmaceutical R&D, although as most of these models are never published, exact numbers are unknown. 3 The National Institute for Health Research Diagnostic Evidence Co-operatives
The National Institute for Health Research (NIHR) Diagnostic Evidence Co-operatives (DECs) were established in 2013 (superseded by the NIHR MedTech and In vitro diagnostic Co-operatives in 2018) and provided £4 million funding over 4 years across 4 institutions (Imperial College London, University of Leeds, University of Oxford, and Newcastle University), in partnership with local National Health Service (NHS) organizations. Their aim was to make clinical and academic expertise available to developers of medical tests, to catalyze the generation of high-quality evidence. 5 A substantial proportion of this work involved collaborating with technology developers as independent partners on evidence-generation projects. The resulting 8 projects, all of which involved early economic modeling, form the basis for this discussion article. Figure 1 summarizes the decision problems considered. Most tests were being developed for secondary care settings, with cancer being the most common clinical area (4 cases), followed by infection (2 cases). Five of the tests were in vitro diagnostics evaluating biomarkers from patient samples, and 2 were genetic tests, with 1 imaging technique. Four of the evaluations have been published.
The aim of this article is to describe the experiences of the NIHR DECs in applying early economic modeling to diagnostics and discuss its strengths and challenges. The structure of the article is as follows. The first section outlines the modeling projects in question. The following section describes our experiences using early modeling methods and what we consider to be the strengths and challenges of these methods. We then explore the outstanding questions around the methodological soundness of early modeling for diagnostics. Finally, we offer guidance on how to maximize the usefulness of these methods, before concluding.
Experiences
Our experiences can be grouped into 3 core areas that summarize the ways in which early modeling of diagnostics differs from late cost-effectiveness analysis: Figure 1 Summary of National Institute for Health Research Diagnostic Evidence Co-operative-industry collaborative early economic modeling projects.
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In each of these areas, early modeling was associated with a number of strengths and challenges.
Early Stage of Product Development
Strengths. The early development and evaluation status of a diagnostic technology in the context of early modeling proved to be an advantage for the collaboration of both developers and researchers. Predominantly, this came in the form of a willingness for test developers to be responsive to the results of the analysis. There was strong buy-in from developers, who used the results to inform further development of the technology and ensure the design of devices was fit for purpose within appropriate environments of use. At an early stage, results can be used not only to decide whether to progress with or discard a technology but also to investigate different clinical applications and patient populations before prioritizing the evaluation of a particular application that is likely to bring most value to various health care environments. Hence, researchers felt less pressured to have the ''right'' outcome and, instead, shared possible outcomes that provided developers with a better context for decision making to ensure the test they develop is fit for purpose.
Researchers also felt at greater liberty to investigate the potential added value of the technology when taking a broader perspective than that of the health system, such as including societal costs and outcomes. This additional information, although not routinely considered in later Health Technology Assessment (HTA), could provide additional insights into potential mechanisms of benefit to inform further R&D. For example, the OPTIMA prelim model helped us to understand that capturing the effect of the test on employment might affect a proportion of the patient population. 8 Challenges. Although the models and research teams were funded independently of their industry collaborators, reducing the pressure to find the ''right'' results, working with companies whose device development process was high risk remained a challenge. Compared with pharmaceutical companies, device developers are often small companies with very few devices. Smaller companies are at risk of being bought out or losing members of staff to other ventures. Hence, there can still be pressure to produce evidence that supports financial stability and company growth. This lack of size and stability, alongside the time constraints imposed by this particular funding call, also increased the need for results to be produced rapidly, which can conflict with the need to invest significant time in model development to produce valid and robust results.
Uncertain or Flexible Clinical Pathway
Strengths. Introducing a diagnostic into a pathway where none previously existed, as many of these technologies intend, gives rise to a host of challenges when trying to map out the clinical care pathway and establish the consequences of testing. Measures of clinical utility require evidence of treatment effectiveness in patients who receive both accurate and inaccurate test results. These cannot be ascertained if previously no test was used. In addition, although a reference test or comparator may exist, it may not have been used in the target pathway, for example, for reasons of cost or ethics (if the reference is invasive). A relevant comparator may have been used only in a different setting, such as when tests are transposed from secondary care to primary or community care. The second panel on cost-effectiveness in health and medicine recommends that all relevant comparators be included, including those that are not currently used in the care pathway under evaluation. 10 As a result, the consequences of introducing a new test are difficult to benchmark and are highly uncertain. Collaboration between developers, research teams, and specialist clinical teams when grappling with these issues is essential.
Clinical expert opinion was used to identify potentially appropriate strategies of the diagnostics, in terms of the clinical decision point (when it is most cost-effective to test), patient subgroup (in whom), and retesting options (how often, such as when the biomarker changes over time or in response to treatment). For example, for the thromboelastography (TEG)-like device, NICE had identified applications in cardiac surgery, trauma, and obstetrics, but clinical expert opinion identified further applications in intensive care units, elderly care, and general surgery.
Expert opinion can also be used to refine the strategies modeled. For example, in the chronic obstructive pulmonary disease (COPD) model, the clinical value of early detection of acute exacerbations in primary care was considered to be low by the general practitioners consulted. Instead, the modeling focused on treatment stratification, in which opportunities both to improve health outcomes and to reduce antibiotic prescribing were identified.
Use of clinical opinion to refine potential test strategies is crucial because the computational and evidence requirements necessary to evaluate all possible options would be overwhelming in most cases (although this has been tried previously 11 ).
Possible barriers to adoption beyond clinical utility were also highlighted, such as work flow issues and ergonomics. Human factors research was used in the case of the TEGlike device to explore how testing is performed in this hospital setting, with the aim of informing device design. In 1 case (carbapenemase-producing enterobacteriaceae [CPE] testing), early identification of potential barriers to adoption informed not only future product development but also the company business plan and marketing strategy. Again, this is outside the realm of later HTA but was able to provide support that helped ensure the developer of a cost-effective technology remains solvent through product development and manufacture.
In aiming to provide information that guides technology development, in addition to informing stop-go decisions, early modeling allows flexibility. Where the value of a technology has not been fully characterized, there is space to explore a range of outcomes, both interim and final, according to test developers' and decision makers' evidence needs at the time of the analysis. While costutility analysis remains important in this area, researchers also used cost-consequence and budget impact analyses where these were relevant.
For example, in the case of CPE testing, the model was designed to estimate the proportions of the patient cohort that would be identified as true or false positive and true or false negative by each method of testing. The company involved in developing the diagnostic test found it useful to consider not only expected costs but also diagnostic outcomes and to consider the impact that prevalence of the condition and test accuracy could have on these outcomes. This allowed exploration of the role of screening in differing regional scenarios in which prevalence is likely to be higher than the current national average.
Challenges. Most projects received some clinical support to inform the structure of the model as well as the validation of the completed model, but this was usually limited to local experts because of time and resource constraints. This may limit the applicability of the evaluations to the NHS as a whole, particularly in areas where national guidance does not exist, and as a result, local care pathways may vary. In some cases, for example, in which delayed prescribing is used, this could increase structural uncertainty in the model, in addition to parameter uncertainty. This was noted in the COPD project, in which antibiotic-prescribing guidelines for COPD are set by the local clinical commissioning group rather than coordinated nationally.
Where best practice guidelines do exist, they may not reflect actual clinical practice, particularly as NHS Trusts have differing priorities. This may in fact provide the motivation for developing a new diagnostic, if the existing one has a high patient burden and poor implementation as a result. Furthermore, access to care pathway evidence sources such as Map of Medicine, a resource providing access to clinical care pathways at the point of care, is limited and requires funding. 12 In addition, data about the accuracy of the test under evaluation-when availablewere often from studies conducted outside the United Kingdom, with different prevalence and incidence rates.
Finally, in the case of the interaction between tests and treatments used in sequence (for example, if a rulein test is followed by a rule-out test), tests are frequently evaluated only in isolation. There is a lack of established methods for modeling this interaction. 13 
Limited Evidence Base
Strengths. There is no reason why an evaluation of a test at a single decision point in the care pathway cannot be applied to any other test that could be used at this decision point, with minor adjustments for accuracy, cost, and adverse events from testing. Given the prevalence of ''fast followers'' in this segment of biotechnology, the ability to use established models to evaluate new tests, or even provide generic benchmarks for cost and accuracy, is a clear advantage of decision modeling and a way of reimbursing the additional time spent creating often-complex models. A more fully developed model also opens up opportunities for exploring uncertainty through sensitivity analysis. The more parameters (such as potential outcomes) that are effectively included, the more their contribution to cost-effectiveness can be explored. This proved to be particularly informative in the COPD model, where the main recommendation-to generate evidence of clinical utility via a trial-was entirely informed by the results of 2-way sensitivity analysis.
Another advantage is the ability to refine and update these more flexible models as evidence becomes available. This could enable greater evidence generation efficiency in later stages of development.
Regarding the method of evaluation, investment in a comprehensive model could facilitate advanced analyses such as value-of-information (VOI) analysis. VOI is an increasingly popular tool that can be used to generate information regarding the value of further investment into research, providing information that complements sensitivity analysis. 14 Within the early modeling context, VOI can be used to identify key parameters in the model that are driving uncertainty around the expected costeffectiveness outcomes and thereby direct the focus and design of future research and development activities. 15, 16 VOI formed the basis of the recommendations of 2 projects outlined here (OPTIMA and AKI).
Challenges. The downside of developing flexible, iterative models that follow a test through their development is that well-executed early models are not necessarily faster, easier to implement, or less complex than models carried out at the late stages of technology development. This is unsurprising for 2 reasons. First, for VOI and effective sensitivity analysis to be conducted, a model needs to describe an intervention's effects on outcomes as accurately as possible. Second, if the intention is for the model to be iteratively developed and reanalyzed throughout the pipeline as new evidence becomes available, then for this process to be efficient, the early model must resemble as closely as possible the late model it will eventually become.
A further challenge is the limited data not just for populating the model but also to fully characterize the technology, for example, shelf life and ease of use, which may affect implementation. Flexibility is both an advantage and a challenge for evaluators using the model results, as there are many more possible scenarios to model.
It is also difficult to validate such models, particularly in relation to current treatment effects that are informed by a large number of assumptions. The plausibility of these assumptions was not always easy to assess. For example, if a patient population has never been differentiated by testing before, because no diagnostic exists, then the difference in average outcomes in the 2 groups is almost impossible to model, even though it may be critical for determining the cost-effectiveness of the test.
Within the conventional cost-utility framework used in economic evaluation, diagnostic technologies face an additional hurdle compared with treatments. To demonstrate an impact on clinical outcomes, a diagnostic must change clinical decision making. However, clinicians and patients frequently overrule test results, particularly in primary care, with the result that test cost-effectiveness is reduced. This aspect of clinical and patient decision making is either ignored or often overlooked in its impact on costeffectiveness, with the assumption being that technologies are perfectly implemented and results are fully followed.
Methodological Developments Needed
Our experiences have highlighted a number of limitations in current methods and shortfalls in the available evidence that require addressing in order to fully realize the potential of early modeling for diagnostic development and evaluation. These cover clinical pathway mapping, model transparency, and modeling sequential testing.
Pathway Mapping
Most significantly, modeling diagnostic tests requires a comprehensive understanding of how a test will alter patient care. Diagnostics have a largely indirect effect on health outcomes, and consequently, evidence is needed to understand the full scale of the effects of testing on health outcomes and costs. While some pathways, such as the bowel cancer screening program, have clear guidance on treatment following testing (and therefore a mechanism of benefit), other clinical areas lack this. For example, the COPD exacerbation management pathway in primary care was found to be highly variable, based on evidence from national and international guidelines, epidemiological evidence, and clinical expert opinion. Notably, which patients received antibiotics and how they were followed up and, if necessary, given further treatment was unclear and highly variable between evidence sources. In this case, currently available evidence, even based on routinely collected data, did not fully capture current clinical practice, and understanding and parameterizing the likely benefit of testing were thus more difficult. The solution was to include the uncertainty in the model and, when this uncertainty affected cost-effectiveness, use this to support additional primary research into clinical decision making in this care pathway, which is ongoing.
A number of the projects addressed this issue by using extensive care pathway-mapping exercises, usually involving expert elicitation. 17 All the projects took a slightly different approach to this mapping, depending on both the setting in question and the methodological preferences of the researchers. A valid, consistent approach to the pathway-mapping process that provides guidance on combining published evidence with expert opinion would improve this.
Model Transparency
Another improvement would be greater transparency around models. Model registries, in which all the information necessary to replicate and critically appraise a model is published online, are of increasing interest. 18 The presence of model registries and open models could increase the efficiency of projects and provide a path to greater consistency between evaluations. Model building is a resource-intensive exercise. It relies on a substantial number of assumptions, and when considering multiple models of interventions in the same care pathway, it relies on an assumption of commonality: that a treatment that is cost-effective would fundamentally be so in all models and vice versa. Registries and open, or shareable, models would improve this commonality.
Registries and greater sharing would also enable use of more specialized model structures, such as dynamic transmission models for infection-assuming the model documentation is also transparent and comprehensible. Two of the models developed were for tests that were expected, and intended, to have some impact on antimicrobial resistance (AMR). Modeling the impact on AMR is likely to be an increasing requirement for diagnostics modeling, since the publication of the O'Neill report-a UK government-commissioned report that explored the likely global health and economic consequences of AMR-concluded that all antibiotic prescribing should be preceded by testing. 19 The need to include AMR in economic evaluation is recognized, but methods for doing so are not yet well-developed. 20 
Sequential Tests
Finally, none of the care pathways modeled here relied on a single test to exclusively guide treatment, but diagnostic evidence overwhelmingly evaluates tests in isolation, compared with a reference standard. The assumption that there is independence between the multiple tests used may overestimate the diagnostic accuracy of the pathway. 21 Ultimately, these issues affect decision modeling at all stages of product development and are not limited just to diagnostics. However, their presence is felt acutely in early diagnostic modeling, where the issues compound in the absence of the cushion of better evidence.
Outstanding Questions around How and When Early Models Should Be Used for Diagnostics
Although some of the challenges outlined above can be addressed through better evidence and methods development, others raise normative questions around the purpose of modeling.
Although early economic modeling can be useful to inform the key decisions in the development of a new technology, caution is required when making decisions on the basis of inevitably weak or limited evidence. This raises the question of what the minimum evidence requirements are to build an early economic model and what decisions can be made on the basis of this exercise.
Most of the companies we worked with had at least some data on test accuracy, but none had information on the downstream consequences of the resulting treatment decisions and how testing may affect these. Modeling can fill this gap if other evidence sources on treatment effectiveness are available, but this evidence was not always available, and the regulatory and funding landscape does not appear to be in place to incentivize its generation, given the overwhelming focus in the diagnostics industry on CE marking and market authorization based solely on diagnostic accuracy. 2 There is also a balance to be struck between complex models that can be adapted over time, and efficient, simple models that can answer specific questions rapidly. In some cases, the tests under evaluation could be of potential value in multiple care pathways or at multiple points in the same care pathway. For example, the imaging agent under evaluation had potential value within a bowel cancer screening program and also in patients under surveillance for inflammatory bowel disease and Lynch disease. Models for multiple care pathways were built, but this was challenging given the time frame and financial constraints. It may have been more pragmatic to do a very simplistic decision tree analysis for each pathway initially to narrow down the focus of the early economic analysis, but the validity of such an approach is unclear.
Finally, as access to linked big data slowly becomes more of a reality, electronic health care records could be used to give a more realistic real-world clinical pathway to inform the structure of early economic models. However, the risk is that this will result in a very complicated analysis, as patients rarely conform to a single recommended clinical pathway. This has recently been demonstrated by a mining exercise to determine real-life clinical pathways during chemotherapy in which 474 different pathway variants were identified among 535 patients with breast cancer. 22 That said, if current models of care pathways are not sufficiently representing the complexity of real-world clinical practice, it could be argued that neither are the results of our analyses.
Advice for Researchers Considering Early Modeling for Tests
Based on these experiences, existing good practice guidelines, and discussions we have had in developing this article, we have outlined a number of recommendations for health economists and their collaborators when developing early models of diagnostics ( Figure 2 ).
Establish the Key Questions to Be Answered
This is an established requirement of economic models generally. 23, 24 However, in an early model, the range of decision problems to be addressed may be broader, including risks to continuing development, headroom in terms of diagnostic accuracy or price, and budget impact.
If a simplified modeling approach is necessary because of a significant lack of relevant evidence, it can still be informative and useful from the developer's perspective. This was seen in the case of CPE testing. Relevant early information gathering, even if only informally (e.g., on the burden of testing on patients or clinicians), can identify risks and barriers to adoption of the technology at an early stage.
To facilitate this, the key purpose of the model should be addressed before embarking on its development. This will enable identification of the relevant outcomes, time horizon, and perspective to consider, as well as the most appropriate analysis to use (e.g., headroom analysis, cost consequence, effectiveness, or utility analysis).
Develop a Model That Reflects the Care Pathway
A fully developed model can be developed and updated alongside the research being carried out over time. Often, lack of data availability and time pressures at early stages of product development result in a simplified approach to modeling. However, early investment in a model that can capture all the components of a test/ treatment pathway as accurately as possible will increase efficiency later in the process, as the model will have the scope to absorb new evidence without the need for complete redevelopment.
An early model can easily be misinterpreted as a ''quick and dirty'' analysis but in fact may be more valuable when it is a full analysis that can be iteratively updated as further evidence becomes available. As outlined in the previous section, while diagnostic accuracy is often assumed to be the key parameter in diagnostic models, 25 there are other ways in which diagnostic technologies can lead to downstream changes in patient health. This finding was reflected in our experience, in which linking test results to clinical outcomes was found to be a critical determinant of cost-effectiveness in almost all cases.
Of course, funding is not unlimited, and research resources must be prioritized, but the long-term efficiency that could result from early and iterative model development could make this an appealing goal for funders. Where a full model is not possible, establishing key questions as outlined above will guide the most effective alternative analytical approach.
Early and Frequent Stakeholder Engagement
Early engagement with relevant stakeholders (e.g., clinicians, laboratory managers, policy makers, and patients) can ensure that the care pathway modeled adequately reflects current practice and that the new pathway proposed is plausible, acceptable, and generalizable. Stakeholders can also provide insight into the limitations of a plausible model. Consideration of expert opinion can also help identify the relevant outcomes (e.g., health and cost outcomes and NHS resource use) likely to be affected by the introduction of the new technology and therefore help to identify the optimal role(s) and setting(s) of the new test, which may directly inform product requirements and therefore future development.
If possible, continued engagement with clinical stakeholders throughout model development and analysis can ensure sense checking of the inputs and outputs of the model. An added advantage of engagement with relevant stakeholders is that barriers and facilitators to implementation can be identified and enable the developer to take steps to overcome them. 
Use Adaptive Review Methods
Systematic review methods are commonly used to inform model structure and quantify model parameters in rigorous health economic modeling studies. However, these approaches may be too resource intensive for models at an early stage, especially if initial searches reveal a limited evidence base, as was the case with the COPD project. Here, rapid review methods proved more efficient.
Accordingly, most projects used targeted literature searches, in which searching and screening were conducted iteratively, rather than following a fixed protocol, to allow for flexibility. This was combined with stakeholder consultation to rapidly inform model structure and parameterization. It is important to allow enough time in the model-building process to supplement searching with expert elicitation and stakeholder consultation to fill in the gaps.
Include Meaningful Sensitivity Analysis
Uncertainty in both model structure and input parameters is inevitable in decision modeling. Early modeling of diagnostics amplifies this uncertainty, first through lack of evidence and second through the additional layer of uncertainty required in modeling diagnosis and treatment. Conducting deterministic 2-and 3-way sensitivity analysis over plausible values of input parameters can identify potentially important thresholds, such as the maximum price of a test, the minimum necessary diagnostic accuracy, and the interaction between the two. The results of such an analysis are likely to be more meaningful than the headline incremental costeffectiveness ratio, by providing evidence for decisions, such as price, that are still within a developer's control. The outcomes of deterministic sensitivity analysis in the COPD project also emphasized the need for treatment effectiveness evidence, the strongest recommendation provided by that research.
Probabilistic sensitivity analysis has value in assessing the impact of the overall uncertainty of the model parameters on model outputs, although it is likely to simply (and inevitably) tell us that cost-effectiveness is highly uncertain. It is more useful when used as the basis for VOI to inform future research. Probabilistic sensitivity analysis was the basis of the VOI in both the AKI and OPTIMA models and formed the basis of research recommendations. An early sensitivity analysis plan may prove useful in ensuring the most relevant information is interrogated.
Conclusion
Diagnostic tests are a pivotal component of the muchmooted paradigm shift toward personalized health care. They are also complex to research, develop, and evaluate, with high barriers to adoption. As such, we believe that more intelligent approaches to research and development for tests are necessary for the realization of the benefits of test-based decision making. The NIHR DECs have demonstrated the usefulness of early consideration of the impact of a test on clinical pathways and its likely implications for clinical and economic outcomes. We believe this approach should be part of the core strategy in the movement toward more efficient research design and timely delivery of high-value and evidence-based diagnostic products for patient care.
